Corbus Pharmaceuticals Holdings (CRBP) Equity Average (2014 - 2025)

Corbus Pharmaceuticals Holdings' Equity Average history runs 12 years deep, the most recent figure standing at $119.8 million for Q4 2025.

• In Q4 2025, Equity Average fell 18.19% year-over-year to $119.8 million; the TTM figure through Dec 2025 stood at $119.8 million (down 18.19% YoY), while the FY2025 annual figure was $145.0 million, up 113.93% from the prior year.
• Equity Average was $119.8 million for Q4 2025 at Corbus Pharmaceuticals Holdings, up from $101.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $146.5 million in Q4 2024 to a low of -$3.3 million in Q4 2023.
• Historically, Equity Average has averaged $73.1 million across 5 years, with a median of $70.9 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Equity Average tumbled 108.8% in 2023, then surged 4542.98% in 2024.
• A 5-year view of Equity Average shows it stood at $73.4 million in 2021, then plunged by 48.93% to $37.5 million in 2022, then sank by 108.8% to -$3.3 million in 2023, then soared by 4542.98% to $146.5 million in 2024, then slipped by 18.19% to $119.8 million in 2025.
• The last three Equity Average figures came in at $119.8 million (Q4 2025), $101.6 million (Q3 2025), and $119.0 million (Q2 2025), per Business Quant data.